Life sciences · 2025
MLN4924, neddylation inhibitor suppresses hypoxia induced retinal angiogenesis by targeting Human Antigen R signaling.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mohan Sruthi Priya, NareshKumar R N, Cheruvu Sai Shreya, Nagarajan Hemavathy, Majid Nishath Fathima, Ranganathan Sampathkumar, Nirmal Jayabalan, Ramasubramanyan Sharada
Аннотация
PURPOSE: Retinal hypoxia is a key pathological stimulus for neovascularization, leading to abnormal proliferation of blood vessels and vascular endothelial dysfunction leading to vision threatening conditions. The anti-angiogenic potential of MLN4924, a specific inhibitor of neddylation signaling has been evidenced in cancer cells, but remains abstract as therapy for ocular angiogenesis in normal retinal cells. The current work intended to delineate a novel molecular signaling cascade of combating retinal angiogenesis by inhibiting the neddylation-Human Antigen R (HuR) signaling pathway using MLN4924.
METHODS: The effect of neddylation inhibition on hypoxia-induced HRMVEC was demonstrated by the real-time PCR, western blotting, immunofluorescence, and functional assays. In silico analysis was used to study the impact of the mutation of the RNA binding protein, HuR neddylation sites on its binding affinity towards VEGF mRNA. RNA immunoprecipitation and Actinomycin D experiments were performed to evidence the effect of neddylation inhibition on HuR binding and stabilization of VEGF mRNA in hypoxic HRMVECs.
RESULTS: Functional angiogenic assays revealed that treatment with MLN4924 could suppress hypoxia-induced angiogenesis by reducing secretory VEGF levels without altering the barrier integrity of HRMVECs. In silico analysis revealed that mutation of two of the HuR neddylation sites decreased its binding affinity to 3'UTR region of VEGF mRNA. Indeed, HuR preferentially bound and stabilized VEGF mRNA upon hypoxia, which was significantly inhibited using MLN4924 in HRMVECs.
CONCLUSION: Neddylation inhibition could suppress hypoxia-induced angiogenesis through HuR signaling without compromising the barrier integrity of HRMVECs.
METHODS: The effect of neddylation inhibition on hypoxia-induced HRMVEC was demonstrated by the real-time PCR, western blotting, immunofluorescence, and functional assays. In silico analysis was used to study the impact of the mutation of the RNA binding protein, HuR neddylation sites on its binding affinity towards VEGF mRNA. RNA immunoprecipitation and Actinomycin D experiments were performed to evidence the effect of neddylation inhibition on HuR binding and stabilization of VEGF mRNA in hypoxic HRMVECs.
RESULTS: Functional angiogenic assays revealed that treatment with MLN4924 could suppress hypoxia-induced angiogenesis by reducing secretory VEGF levels without altering the barrier integrity of HRMVECs. In silico analysis revealed that mutation of two of the HuR neddylation sites decreased its binding affinity to 3'UTR region of VEGF mRNA. Indeed, HuR preferentially bound and stabilized VEGF mRNA upon hypoxia, which was significantly inhibited using MLN4924 in HRMVECs.
CONCLUSION: Neddylation inhibition could suppress hypoxia-induced angiogenesis through HuR signaling without compromising the barrier integrity of HRMVECs.